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Fine-needle aspiration (FNA) is a well-established method for
diagnosing breast cancer which has recently been successfully
combined with molecular and cytogenetic analysis (Ljung et al,
1994). c-erbB2/neu overexpression is usually detected by the
immunocytochemical (ICC) technique, although the methodo-
logical and specimen variability, and differences in antibody sensi-
tivity, make this technique not entirely reproducible and, therefore,
not highly reliable (Troncone et al, 1993; Corkill et al, 1994; Press
et al, 1994; Midulla et al, 1995). On the other hand, the quantifica-
tion of c-erbB2/neu copy number with semi-quantitative poly-
merase chain reaction (PCR) (Lonn et al., 1996) does not allow the
performance of a ‘cell by cell’ analysis and the evaluation of gene
distribution. The feasibility of dual-colour fluorescence in situ
hybridization (FISH) on cytological material from FNA
(performed on thawed tissue samples using a 24-gauge needle) has
already been described (Sauter et al, 1996). Similarly, one-colour
FISH on archival cytological samples up to 94 days old has been
successfully performed (Cajulis et al, 1996). We have recently
started to perform FNA for TP53 molecular analysis in a number
of patients candidate to primary chemotherapy for breast cancer
(Lavarino et al, 1998). In this paper, we further developed a
cytogenetic approach applying dual-colour FISH analysis of
c-erbB2/neu (Kallionemi et al, 1992) to material obtained from
the same pass from the same patient series and to a new series.
c-erbB2/neu, which is located on chromosome 17q11.2-q12 and
chromosome 17 pericentromeric probes, were co-hybridized on
fresh cytological smears and, when the latter were not available,
on destained smears. A number of cases, of which fresh frozen
material was available, were also analysed for c-erbB2/neu over-
expression by means of conventional ICC technique. The purposes
of this analysis were as follows: (i) to verify the feasibility of a
molecular-cytogenetic analysis for c-erbB2/neu gene amplifica-
tion on FNA material, (ii) to verify the possibility of using frozen
and/or destained smears, and (iii) to compare molecular-cyto-
genetic and ICC results. The results show that dual-colour FISH
may be successfully performed on each type of smear. The
quantification and evaluation of spatial distribution and the hetero-
geneity level of c-erbB2/neu amplification among the nuclei
represent an obvious advantage of FISH over ICC. Moreover, the
higher sensitivity and reproducibility, as well as the evaluation
of the chromosome copy number, make FISH unique for the
assessment of c-erbB2/neu gene amplification on FNA material.
MATERIALS AND METHODS
Patients and tumours
Fifty-eight consecutive female patients (age range 25–71 years;
mean 53 years) with primary breast carcinoma ascertained by
FNA, who had entered a primary chemotherapy protocol with
doxorubicin and paclitaxel, were selected for the present study.
According to the tumour node and metastasis classification (TNM;
UICC, 1992), one case was T4bN2M1, one case T4bN2M0, three
cases were T4bN1M1, 12 cases T4bN1M0, one case T3N1M1,
c-erbB2/neu gene and chromosome 17 analysis in breast
cancer by FISH on archival cytological fine-needle
aspirates
A Mezzelani1, L Alasio1, C Bartoli2, MG Bonora1, MA Pierotti3, F Rilke and S Pilotti1
1Divisione di Anatomia e Istologia Patologica e Citopatologia, 2Divisione di Semeiotica Chirurgica e Chirurgia Ambulatoriale, 3Divisione di Oncologia
Sperimentale A, Istituto Nazionale per lo Studio e la Cura dei Tumouri, Via G. Venezian 1, 20133 Milano, Italy
Summary The detection of specific genetic alterations in breast cancer is useful for diagnosing, predicting prognosis and planning
preoperative treatment. c-erbB2/neu overexpression is usually detected by immunocytochemistry (ICC), although this technique is neither
completely reproducible nor highly reliable, owing to specimen and methodologic variability and antibody sensitivity. Here, we combine two
well-established techniques, fine-needle aspiration (FNA) and fluorescence in situ hybridization (FISH), to detect c-erbB2/neu amplification in
patients candidate to primary chemotherapy and, in part, previously analysed for c-erbB2/neu overexpression. Sixty smears from FNA were
used to simultaneously detect c-erbB2/neu and chromosome 17 centromere. FISH was successful in 58 cases and detected 24 amplified
cases, three of which were negative by immunophenotyping, 28 negative cases, with evidence of two normal c-erbB2/neu/ signals, two cases
with deletion of c-erbB2/neu, and four cases with polysomy, thus providing more reliable and informative results than ICC. This study
underlines the advantages offered by the FNA and FISH combination which are two rapid, reliable, simple and informative techniques, to
analyse one of the most important genetic markers for predicting prognosis and chemotherapy planning for breast carcinoma in particular in
the light of the recently proposed trials of primary chemotherapy.
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Correspondence to: A Mezzelanifour cases T3N1M0, three cases T3N0M0, one case T2N2M0,
17 cases T2N1M0, 11 cases T2N0M0, three cases T1N1M0 and
one case T1N0M0. Two patients came from breast cancer-prone
families.
FNA
In each case material was obtained by 10–15 rapid back and forth
motions of the fine needle (21-gauge) within the tumour tissue
nodule performed during a single pass. In one case, material from
both the primary tumour and a nodal metastasis was available, and
in another case from two nodules from both breasts.
Cytological preparations
The aspirated material was partly smeared on slides; one slide was
fixed immediately in 95% ethanol and stained according to the
Papanicolaou method (PAP) (Koss, 1979a), one air-dried and
stained with the May–Grünwald–Giemsa technique (MGG) (Koss,
1979b), for morphologic evaluation, and the other slides were
frozen. The remaining material was resuspended in phospate-
buffered saline (PBS) and frozen.
Additional information (data not shown) was acquired by an
immunocytochemical panel, routinely applied to FNA material in
our institution, encompassing hormonal receptors and proteins
encoded by the BCL2 and TP53 genes. Assessment of estrogen
receptor (ER) and progesterone receptor (PR) was carried out as
previously described (Frigo et al, 1995), and of BCL2 and p53
proteins by monoclonal antibody (mAb) bcl-2,124 (1:1000
diluted) (DAKO, Glostrup, Denmark), and mAb DO7 (1:1000
diluted) (Ylem, Avezzano, AQ, Italy), respectively, as detailed
above.
Immunostaining
Detection of c-erbB2/neu protein expression was performed on
fresh smears using the mAb CB11 (1:1000 diluted) (Ylem,
Avezzano, AQ, Italy). The antibody was detected with the strepta-
vidin–biotin immunoperoxidase method (streptavidin HRP: horse-
radish peroxidase). Briefly, smears were treated with 0.3%
hydrogen peroxide for 20–30 min to suppress endogenous peroxi-
dase. Thereafter, 2% normal human serum was applied for 30 min
as a suppressor serum. The slides were then incubated overnight
at 48C with the primary antibody. After several brief rinses, the
biotinylated secondary antibody (30 min) and streptavidin HRP
were applied in succession. The preparations were then developed
in 3,3-diaminobenzidine solution, counterstained in Carazzi’s
haematoxylin, dehydrated and mounted. On cytological material
c-erbB2/neu staining was interpreted as positive when the whole
cell was decorated with a sharper signal associated with
cytoplasmic boundaries.
Specimens for FISH analysis
Sixty aspirates (one patient had one lymph node and the breast
nodule aspirated, and one had one nodule for each breast) were
analysed: three were frozen smears, 29 were cytospins from frozen
material in PBS suspension, four were cytological smears stained
with MGG and 24 were cytological smears stained with PAP.
Pretreatment of slides
Cytological smears stained with PAP or MGG were destained and
treated prior to in situ hybridization according to Cajulis and
collaborators (1996).
Dual-colour FISH
On each slide, an area of 18 3 18 mm2 was hybridized with the
biotinylated probe c-erbB2/neu (ERBB2) (Oncor, Gaithersburg,
MD, USA) together with the digoxigenin-labelled chromosome
17 a-satellite region (D17Z1) (Oncor, Gaithersburg, MD, USA).
The hybridization was performed according to Lichter (Lichter
et al, 1990) and the manufacturer’s recommendations.
The biotinylated probes c-erbB2/neu were detected by two
layers of avidin–FITC (fluorescein isothiocyanate; Vector,
Burlingame, CA, USA), and chromosome 17 a-satellite by one
layer of rhodamine-labelled anti-digoxigenin (ab) (Boehringer
Mannheim, Germany). Slides were then counterstained by
DAPI (4,6-diamidino-2-phenylindole dihydrochloride hydrate).
FISH results evaluation
The slides were observed at 1000´ magnification. At least 100
well-defined nuclei were scored for each hybridization. Samples
were considered:
Normal: when two c-erbB2/neu related to two chromosome
17 copy number was found in all cells.
Amplified: when c-erbB2/neu copy number per centromere 17
is greater than 2.
Polysomy: when equal numbers of c-erbB2/neu and
centromere 17 signals are present and the numbers are greater
than 2.
Deleted: when c-erbB2/neu are fewer than centromere 17
copies.
Digital signal detection
Image acquisition was performed with a cooled CCD camera
(Photometrics, Tucson, AZ, USA) coupled with a Zeiss Axioskop
fluorescence microscope and controlled by a Power Macintosh
7100/80. Frames of the nuclei were taken separately using the
software package IPLab Spectrum (Signal Analytics).
RESULTS
The results obtained are summarized in Table 1. Both frozen and
PAP or MGG stained cytological smears were suitable for FISH
analysis. c-erbB2/neu probe successfully hybridized 58 out of 60
samples (96%). On the other hand, chromosome 17 pericentro-
meric signals were detectable in 31 out of 60 (51%) slides, most
probably due to technical problems: in fact c-erbB2/neu was
detected with two layers of avidin–FITC while chromosome
17 a-satellite was detected with only one layer of rhodamine-
labelled anti-digoxigenin antibody (so as to avoid background
artefacts). No differences were observed between PAP and MGG
colouring and the different types of slide preparations.
Considering the clinically significant results we observed the
following:
c-erbB2/neu amplification
Twenty-four cases (36.6%) were amplified. All of them showed a
clustered distribution, although a small number of cases also
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was heterogeneous among the nuclei of the same specimen, an
average was evaluated and the cases were then subclassified on the
basis of the results obtained.
Very low level of amplification: only one case, with 4–5 c-
erbB2/neu signals out of two chromosome 17, presented a
very low level of gene gain in 10% of the cells (Figure 1 C,D)
Low level of amplification (from 6 to 15 signals): seven cases
were found
Medium level of amplification (from 16 to 30): ten cases
showed this grade of gene amplification.
High level of amplification (more than 30 signals): only four
cases showed this c-erbB2/neu amplification.
Moreover, five cases revealed two normal chromosome 17, four
cases (which resulted aneuploid by ploidy analysis), (Lavarino et
al, 1998), showed polysomy of chromosome 17, one case had only
one chromosome 17 and the remaining eight were not available for
this parameter.
Normal c-erbB2/neu
Twenty-eight cases (43.3%) showed two c-erbB2/neu signals. In
15 of them the signals were related to two chromosome 17, and in
the remaining 13 cases the chromosome 17 was not detectable.
c-erbB2/neu deletion
Two cases (6.6%) showed c-erbB2/neu deletion. The first one had
one c-erbB2/neu signal related to a monosomy of chromosome 17,
and the second had two c-erbB2/neu signals out of three chromo-
some 17.
c-erbB2/neu polisomy
Four cases (6.9%) showed polysomy of the gene linked to the
polysomy of chromosome 17. The level of polysomy among the
four cases ranged from trisomy up to 7–8 chromosome 17 and was
related to an equal number of c-erbB2/neu copies.
All samples but one (see Very low level of amplification), scored
as amplified, polysomic or deleted showed the genetic anomalies
in at least 20% of the cells. All samples with gene amplification,
polysomy or monosomy exhibited a high level of heterogeneity
among individual cells. In spite of fine-needle aspirates, cells
directly from the node, a contamination of blood cells or healthy
tissue cells is frequent making cell population heterogeneous. On
the other hand, in case of amplification, the variability of gene
copy number among the tumour cells of the same specimens
reflect genetic instability and may be an important characteristic of
solid tumours since genetic instability is essential for tumour
evolution (Sauter et al, 1996).
Comparison between FISH and ICC (Table 2)
ICC analysis was carried out in 47 cases with available frozen
smears and/or cytospin preparation. FISH results were concordant
with previous ICC estimates in 44 cases. Three cases, negative for
overexpression, appeared to be amplified by FISH. One case
showed a very low amplification (consisting in 4–5 c-erbB2/neu
signals out of two chromosome 17). As for the other two cases,
FISH results showed a high level of amplification in contrast with
the negative overexpression.
DISCUSSION
Primary chemotherapy alone, or combined with radiotherapy, is
being progressively widely applied to reduce mutilating surgery
in the treatment of patients with breast carcinoma (Bonadonna
et al, 1990; Rilke et al, 1996). Breast carcinomas that overexpress
c-erbB2/neu are more aggressive (De Potter et al, 1995), less
responsive to CMF-containing adjuvant therapy regimens
(Gusterson et al, 1992), may benefit from high-dose adjuvant
chemotherapy (Muss et al, 1994) and, when steroid receptor posi-
tive (Pietras et al, 1995), may be unresponsive to tamoxifen
(Hynes et al, 1994) or to tamoxifen with radiotherapy (Sjogren
et al, 1998). Moreover, Press and collaborators (1997), have
demonstrated that c-erB-2/neu is an independent predictor of poor
clinical outcome and, more recently, the Toronto Breast Cancer
Study Group has found that c-erbB2/neu amplification is an
independent prognostic factor for risk of recurrence in axillary
node negative breast cancer (Andrulis et al, 1998). Recent clinical
studies, in keeping with preclinical evidence (Harwerth et al,
1993; Baselga et al, 1996), have shown some benefits in stage IV
c-erbB2/neu overexpressing breast carcinomas treated by recom-
binant humanized monoclonal (rhmAb) c-erbB2/neu (Baselga
et al, 1996). In this scenario, reliable information on c-erbB2/neu
overexpression, in addition to other biological markers, becomes
determinant in both predicting prognosis and planning treatment.
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Table 1 Results obtained by FISH analysis on 58 of 60 cases stored frozen and destained smears, of c-erbB2/neu related to chromosome
17 copy number
No. of cases with:
c-erbB2/neu No. of cases Normal Monosomic Polysomic Chromosome 17
(%) chromosome 17 chromosome 17 chromosome 17 not evaluable
Amplified 24 (41.4) 15 1 4 14
Normal 28 (48.3) 5 0 0 13
Deleted 2 (3.4) 0 1 1 0
Polysomic 4 (6.9) 0 0 4 0
Total 58 20 2 9 27
Table 2 Results obtained with ICC and FISH in 47 cases
c-erbB2/neu
FISH
ICC Amplified Non-amplified
Overexpressed 17 0
Non-overexpressed 3 27
Total 20 27522 A Mezzelani et al
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Figure 1 (A) A nucleus with two normal c-erbB2/neu signals related to two normal chromosome 17 copy number shown in (B). (C) A nucleus with a very low
level of gene amplification (5 spots) out of two chromosomes 17 shown in (D)
Figure 2 (A) A nucleus showing a c-erbB2/neu amplification; it is noticeable that amplification has happened only in one of the two chromosome 17 shown in
(B), as the other one has a normal single copy of the gene. (C) A case of c-erbB2/neu deletion that is related to a chromosome 17 deletion shown in (D)In our experience, the selective plasma membrane immuno-
reactivity of c-erbB2/neu protein shows a poor reproducibility on
fresh or cryopreserved FNA material. Therefore, this gene product
is not currently used for our pretreatment immunophenotyping
panel routinely applied to patients meeting the criteria for primary
chemotherapy, and which includes the assessment of hormonal
receptors, the MIB1 growth fraction, and the proteins encoded
by TP53 and BCL2 genes. Furthermore, the literature data on
c-erbB2/neu immunoreactivity applied to cytology are contradic-
tory; in fact, even though a higher cytological sensitivity is shown
over histology (Corkill et al, 1994; Troncone et al, 1996), some
authors claim that immunostaining performed on destained smears
(Corkill et al, 1994;) are more informative, while others support
fresh material immunostaining (Troncone et al, 1996). More
worrying, the data on c-erbB2/neu overexpression in these
cytology-based studies appear to largerly exceed (Troncone et al,
1993; Midulla et al, 1995) those based on molecular-histologic
investigations, which yield a positive rate of 10–40% of cases
examined (De Potter et al, 1995; Rilke et al, 1991). Such inconsis-
tencies in antibody sensitivity and possible cross-reacting artefacts
(Rilke et al, 1991; Press et al, 1994; Bobrow et al, 1996), prompted
us to identify a more reliable and independent technique to
complement the immunocytochemical panel data.
Our results show a fairly good correlation between c-erbB2/neu
overexpression and gene amplification: all cases with positive
immunostaining were amplified. In our study, however, three
immunophenotypically negative cases, showed gene amplification
by FISH: one showed a very low amplification in only 10% of the
nuclei, which probably cannot be detected by the antibody while
the second had a high degree of gene amplification which
prompted us to re-examine the case that, following respect
immunostaining, proved positive. The third was one of the two
breast nodules of the same patients: both nodules showed a high
level of amplification by FISH, but only one was positive by ICC.
These results confirm the reliability of FISH analysis. Moreover, a
negative FISH, compared to conventional ICC, has the advantage
of presenting ‘two signals’ (or only one in case of deletion), that
discriminate between a true negative result and the failure of the
hybridization procedure. Moreover, as c-erbB2/neu amplification
has prognostic significance, the possibility to quantify the level
of gene amplification could better correlate in predicting
prognosis.
FISH also allows the determination of spatial distribution of
amplified genes, distinguishing between clustered and diffuse
types of distribution. The first is suggestive of an intrachromo-
somal location of the gene copies, whereas the second is sugges-
tive of an extrachromosomal location in double minutes (DM)
(Kallionemi et al, 1992). Since preclinical evidence has shown that
a low concentration hydroxyurea-based treatmentmay reduce
extrachromosomic amplifications and tumour cell tumorigenicity,
we could therefore speculate that DMs should represent an
important target for chemotherapy (Von Hoff et al, 1992).
Another advantage of dual-colour FISH analysis is that the
chromosome 17 copy number is simultaneously characterized,
adding some prognostic information. As for chromosome 17
polysomy, it has been demonstrated that polysomy identified by
FISH is related to DNA aneuploidy which in turn, in breast
carcinoma, is related to a poor prognosis (Gnant et al, 1993). In
fact, all our cases that were polysomic by FISH were aneuploid
by static analysis of DNA content (Lavarino et al, 1998).
Furthermore, in our (data not shown) and in another experience
(Kallionemi et al, 1992), c-erbB2/neu overexpression may occur
in association with polysomy. The significance of this type of
overexpression has not been investigated in a clinical setting.
In the case of deletion of chromosome 17, there is the loss of
several tumour suppressor genes located on this chromosome,
including nm23, the familial breast cancer gene BRCA1, and
TP53. Tumour suppressor genes are frequently inactivated by the
deletion of one allele and the mutation of those remaining. Hence,
tumours with a chromosome 17 monosomy present a higher risk of
being, or of becoming carriers of homozygous inactivated forms of
the above mentioned genes (Solomon et al, 1991), in particular
TP53. For this reason, the cases analysed here are also currently
being investigated for TP53 mutational status (Lavarino et al,
1998). The rationale for the definition of these genetic alterations
derived not only from preclinical (Lowe et al, 1993, 1994) and
c-erb B2/neu analysis by FISH on FNA 523
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Figure 3 (A) A case of c-erbB2/neu amplification; two nuclei have gene amplification as one has two normal copies. The same counterstained nuclei are
shown in (B)clinical (Wahl et al, 1996) evidence suggesting a high correlation
between chemotherapy response and TP53 status (Moll et al,
1995), but also from recent in vitro observations, relevant to the
present findings, suggesting that c-erbB2/neu antibody-induced
growth arrest of cancer cells depends on the activity of wild-type
of TP53 (Hansen et al, 1995). If a similar phenomenon happens in
vivo in breast cancer patients, TP53 status will become deter-
minant for the prediction of the therapeutic response to a treatment
with anti-c-erbB2/neu mAb.
In conclusion, our results underline the advantages offered by
the combination of two rapid and very informative techniques,
such as FNA and FISH, in a clinical setting in order to acquire
additional data on genetic markers useful for the prediction of
prognosis, for the planning of more individualized treatments and
for the evaluation of therapy response (Goldhirsch et al, 1995).
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